SNYNF
Sanofi
$88.50
+3.69%
No data for this timeframe.
Vol
SEC Reports2
Recent Activity
Apr 27, 2026
SEC
Sanofi's 6-K filing reports multiple regulatory catalysts: FDA approval of Dupixent for young children with chronic spon
6-K — Impact 7/10
Apr 23, 2026
SEC
Sanofi reported strong Q1 2026 results with 13.6% sales growth and 14.0% business EPS growth at CER, driven by Dupixent
6-K — Impact 8/10
Analyst Ratings
7Strong Buy
11Buy
11Hold
1Sell
0Strong Sell
Latest Reports
BULLISH
6-K
7/10
Sanofi's 6-K filing reports multiple regulatory catalysts: FDA approval of Dupixent for young children with chronic spon
Apr 27, 2026
BULLISH
6-K
8/10
Sanofi reported strong Q1 2026 results with 13.6% sales growth and 14.0% business EPS growth at CER, driven by Dupixent
Apr 23, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 7.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 60% buy across 30 analysts — 7 strong buy, 11 buy, 11 hold, 1 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $10.8B | 8.2% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $13.3B | 6.8% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $46.7B | 7.1% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $49.6B | 6.1% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 7 | 11 | 11 | 1 | 0 | 60% | |
| Apr 1, 2026 | 7 | 11 | 11 | 1 | 0 | 60% | |
| Mar 1, 2026 | 7 | 11 | 11 | 1 | 0 | 60% | |
| Feb 1, 2026 | 8 | 11 | 10 | 1 | 0 | 63% | |
| Jan 1, 2026 | 8 | 13 | 7 | 1 | 0 | 72% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.